Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Showing public results only.
A filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenBMNR said crypto plus cash plus other holdings totaled twelve point three billion dollars as of May 25, 2026. The proof gate is ETH per share, staking yield, cash runway, and NAV transparency.
OpenRigetti has technical credibility and a proposed $100M federal quantum award, but the investment case still hinges on revenue scale, cash burn, fidelity, and system roadmap execution.
OpenD-Wave has one of the clearest customer-demand signals in quantum after record bookings, but the Q1 revenue base remained small and losses expanded.
OpenInfleqtion has a clean quantum identity, record Q1 revenue, and a proposed $100M federal tailwind, but the business still needs revenue scale and operating-loss discipline.
OpenGlobalFoundries has the largest public-market quantum foundry angle in this batch, but investors still need proof that the proposed CHIPS funding and customer engagements become durable demand instead of a one-day headline.
OpenBigBear.ai's Q1 2026 backlog and gross margin improved, but the deep dive keeps the proof gate on revenue conversion, adjusted EBITDA, and operating cash flow.
OpenA refreshed Micron Technology thesis using latest official May 2026 data, Q2 FY2026 results, HBM4 production, AI server memory demand, data-center mix, U.S. manufacturing updates, capex, balance-sheet strength, and cycle risk.
OpenAeva has the kind of customer list lidar startups chase: Daimler Truck, a Top 10 European OEM, NVIDIA, Forterra, Nikon and smart-infrastructure deployments. The catch is that revenue is still $6.3 million a quarter, broad-based deliveries are not expected in 2026, and the bridge is funded by cash, convertible debt and an equity-linked facility.
OpenADI is not a pure AI stock. It is a cash-rich analog semiconductor leader where industrial recovery, automotive resilience, and data-center infrastructure orders are now arriving at the same time.
OpenAxcelis has a focused ion-implant franchise, a sizable installed-base service layer, strong cash and investment liquidity, and Veeco optionality. The hard part is that power and mature-node digestion have pulled revenue down, backlog is lower, export controls matter, and the next leg needs memory strength to become orders instead of just commentary.
OpenOfficial-source baseline for Applied Optoelectronics using SEC submissions, SEC XBRL companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, Q1 FY2026 earnings 8-K and release, 2026 proxy, and optical-networking peer filings.
OpenHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
OpenA Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
OpenAn ASML five-year double thesis focused on EUV scarcity, High-NA adoption, China/export-control risk, bookings visibility, and semiconductor capex cycles.
OpenA Coverage Bootstrap Broadcom company evaluation covering custom AI silicon, Ethernet networking, VMware, free cash flow, customer concentration, integration risk, and valuation discipline.
OpenA Broadcom five-year double thesis focused on custom AI silicon, Ethernet networking, VMware free cash flow, customer concentration, and integration risk.
OpenA Coverage Bootstrap Bloom Energy company evaluation covering fuel cells, data-center power demand, revenue growth, adjusted EBITDA, margins, project execution, cash flow, and risk controls.
OpenA Coverage Bootstrap Constellation Energy company evaluation covering nuclear fleet economics, clean firm power, data-center PPAs, regulation, fleet reliability, acquisitions, and valuation risk.
OpenA Coverage Bootstrap CRISPR Therapeutics company evaluation covering CASGEVY, in-vivo editing, pipeline optionality, cash runway, commercialization, clinical risk, dilution, and valuation framework.
Open